KORU Medical Q2 revenue up 21%, raises 2025 guidance
Overview
KORU Medical Q2 2025 net revenues rise 21% to $10.2 mln
Gross margin drops to 63.5% on favourable year-ago inventory adjustment, current qtr tariff charges
Adjusted EBITDA turns positive
Outlook
Company raises 2025 revenue guidance to $39.5 - $40.5 mln
KORU Medical reiterates full-year gross margin guidance of 61% - 63%
Company expects positive cash flow from operations for full year 2025
KORU Medical forecasts ending cash balance greater than $8.1 mln for 2025
Result Drivers
DOMESTIC REVENUE GROWTH - Driven by higher consumable volumes and market share gains from new and existing accounts
INTERNATIONAL REVENUE GROWTH - Boosted by higher consumable and pump volumes, prefill patient conversions, and expansion into new markets
PHARMA SERVICES GROWTH - Increased revenues from product sales for clinical trials
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income |
| -$200,000 |
|
Q2 Gross Margin |
| 63.5% |
|
Q2 Operating Expenses |
| $6.80 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for KORU Medical Systems Inc is $6.00, about 45.3% above its August 5 closing price of $3.28
Press Release: ID:nBw5LjJ7la
